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Abstract
Introduction: Network meta-analyses (NMAs) are complex methodological
approaches that may be challenging for non-technical end-users, such as
policymakers and clinicians, to understand. Consideration should be given to
identifying optimal approaches to presenting NMAs that help clarify analyses. It is
unclear what guidance researchers currently have on how to present and tailor
NMAs to different end-users.
Methods: A systematic review of NMA guidelines was conducted to identify
guidance on how to present NMAs. Electronic databases and supplementary
sources were searched for NMA guidelines. Presentation format details related to
sample formats, target audiences, data sources, analysis methods and results were
extracted and frequencies tabulated. Guideline quality was assessed following
criteria developed for clinical practice guidelines.
Results: Seven guidelines were included. Current guidelines focus on how to
conduct NMAs but provide limited guidance to researchers on how to best present
analyses to different end-users. None of the guidelines provided reporting
templates. Few guidelines provided advice on tailoring presentations to different
end-users, such as policymakers. Available guidance on presentation formats
focused on evidence networks, characteristics of individual trials, comparisons
between direct and indirect estimates and assumptions of heterogeneity and/or
inconsistency. Some guidelines also provided examples of figures and tables that
could be used to present information.
Conclusions: Limited guidance exists for researchers on how best to present
NMAs in an accessible format, especially for non-technical end-users such as
policymakers and clinicians. NMA guidelines may require further integration with
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end-users’ needs, when NMAs are used to support healthcare policy and practice
decisions. Developing presentation formats that enhance understanding and
accessibility of NMAs could also enhance the transparency and legitimacy of
decisions informed by NMAs.
Introduction
Transparency is a key principle underlying fair and legitimate health technology
assessment (HTA) processes and related policy decisions [1]. Transparency
requires not only providing sufficient information, but also providing informa-
tion in an accessible and understandable format for end-users. This is especially
relevant when complex methods such as network meta-analyses (NMA) form the
basis of a HTA.
In the absence of head-to-head trials of relevant comparators, NMAs frequently
inform cost-effectiveness evaluations and therapeutic or drug class reviews [2].
One frequently cited concern with NMAs is that the complex statistical methods
do not permit the end user to understand how the results were obtained or if they
are valid [3, 4]. Creating simple but accurate explanations of NMAs for
policymakers, and those impacted by policy decisions such as clinicians and
patients can be challenging. Currently, this is further complicated by the variable
expertise among researchers in conducting and interpreting NMAs [3, 5], the
rapidly evolving developments in NMA methods and restrictions inherent in
different methodological approaches (e.g. Bayesian versus frequentist analyses)
and available NMA software (e.g. WinBugs, STATA, SAS). [6–9] As methodo-
logical standards become more clear for conducting NMAs, guidelines should
begin to consider how best to present and tailor NMAs to different end-users.
Researchers themselves have identified areas of confusion related to NMAs and
non-technical audiences are likely in need of greater support in understanding
NMAs. Although NMAs build on many of the same concepts as traditional meta-
analyses, these similarities are often not recognized and the same critiques that
meta-analyses once faced (e.g. heterogeneity and combining studies) are
frequently applied to NMAs. [10]
Although work is ongoing to develop standards for reporting NMAs and for
critically appraising NMAs, [8, 11–12] consideration should also be given to
identifying optimal presentation formats, i.e. determining not just ‘what’ to report
but ‘how’ best to report it, and how to tailor information to different audiences
who may be unfamiliar with NMAs. While good reporting practices are important
to follow and contribute to clarity and transparency, they may be insufficient for
good communication to non-technical audiences. Although reporting guidelines
used by researchers enhance transparency, experience in the realm of clinical trials
and evidence-based medicine has shown that they are insufficient for good
communication to non-technical audiences and alternate tools and presentation
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formats such as decision-aids and clinical practice guidelines have been developed
for patients and clinicians, respectively. While adequately reporting NMA details
is a first essential step that provides a transparent description of the analysis and
results to the reader, subsequently arranging this information in presentation
formats that assist end-users in their understanding and/or application of the
information is also an important consideration. Developing tools and alternate
presentation formats that enhance the accessibility of NMAs may also be one
approach to increasing their impact and value to clinicians and policymakers.
While standards for transparent NMA reporting should be consistent, regardless
of the audience or topic, different presentations formats may be appropriate for
different audiences or topics. Some studies have focused on helping end-users
such as clinicians interpret NMAs, [13–14] but it is unclear what guidance
researchers have on how to optimally present NMAs to non-technical end-users
such as policymakers.
A number of studies have surveyed current practices for presenting NMAs or
explored different options for presenting NMAs [7, 15–17]. However, determining
what guidance researchers are provided on how to present and tailor NMAs to
different audiences and determining how it aligns with end-users needs is also an
important piece of this puzzle. This can contribute to developing optimal
presentation formats and knowledge translation approaches applicable to NMAs.
[18] A systematic approach to knowledge translation could improve the
accessibility of HTAs that are based on NMAs, thereby enhancing the legitimacy
of and confidence in health policy decision-making processes. [1] Therefore, this
study systematically reviewed current guidelines for conducting or reporting
NMAs to determine what guidance researchers are provided on how to present
NMAs. Our specific objectives were to: (1) determine if researchers are provided
any guidance on how to present a NMA (2) determine if this guidance is targeted
toward non-technical end-users such as policymakers or clinicians and (3)
interpret these findings in the context of non-technical end-users’ needs, who
must apply the results of NMAs to policy or practice decisions.
Methods
Systematic Review
A systematic review was conducted following Cochrane methodology [19].
Guidelines for conducting or reporting on NMAs were included that primarily
targeted statisticians, researchers and others who produce NMAs for the purpose
of informing healthcare policy and practice decisions. In this review NMAs were
defined as ‘‘an analysis that syntheses information over a network of comparisons
to assess the comparative effects of more than two alternative interventions for the
same condition; a network meta-analysis synthesizes direct and indirect evidence
over the entire network, so that estimates of intervention effect are based on all
available evidence for that comparisons.’’ (http://cmimg.cochrane.org/glossary/
1#lettern). This definition encompasses other terminology that may be used
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including both ‘‘indirect comparisons’’ ‘‘mixed treatment comparisons’’ and
‘‘multiple treatment comparisons’’. Formal NMA guidelines as well as interim
guidance documents or working group documents that provided recommenda-
tions and were developed by collaborative groups or organizations with the intent
of informing formal NMA guidelines were included. Studies were excluded if they
were: editorials or opinion papers; original methodological articles on conducting
NMAs; overviews or reviews of existing NMAs; guidelines not primarily focused
on NMAs; or not the most recent or comprehensive versions of the guidelines.
Guidelines on how to interpret or critically appraise NMAs were excluded because
these are targeted primarily towards NMA audiences that must apply the results of
NMAs and would not elicit information on what guidance researchers are
provided on how to present NMAs to different end-users. Outcomes of interest
were the type and frequency of information on presentation formats.
Search Strategy
Databases searched included Medline (1996 to June 2014), EMBASE (1980 to June
2014) and the Cochrane Database of Systematic Reviews, using the earlier date
limit of 2000 but no language restriction. The search concepts were ‘guidelines’,
‘indirect comparisons’, ‘network meta-analyses’ and ‘multiple or mixed treatment
comparisons’. Grey literature was searched for unpublished reports using the
CADTH Grey Matters checklist as a guide, in addition to other relevant resources
[20]. Studies were also obtained through hand searching of selected journals and
authors, reviewing reference lists of potentially relevant studies and suggestions
from experts in NMAs.
Study Selection
Citations were screened for relevance by one review author based on the title and
abstract of identified articles. Two review authors independently reviewed the full
text of potentially relevant guidelines to assess exclusion or inclusion.
Critical Appraisal
Guideline quality was assessed using the AGREE II instrument [21]. AGREE II was
designed, in part, to assess the quality of clinical practice guidelines. No
instruments currently exist to assess methodological guidelines or guidelines for
NMAs. Therefore, minor modifications to the AGREE II instrument were made
for this study (see S1 Table for details).
Data Extraction
One author extracted data, which was verified by a second author and
disagreements were resolved by a third reviewer. The following data were
extracted from guidelines (see S2 Table for detailed variable definitions).
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(1) Guideline characteristics: guideline purpose, guideline scope, general or
disease-specific, target audience, year, geographic region, author affiliations
and; providing a reporting template, sample tables, sample figures or a
glossary.
(2) Presentation formats: details on how to present data sources (evidence
networks, individual trial characteristics, critical appraisal of individual
trials), analysis methods (assumptions, heterogeneity and inconsistency,
methodological concerns) and results (comparison with direct estimates,
uncertainty, rankings, implications of findings). The target audience for
different presentation formats was extracted when available.
Items related to presentation format were selected based on identification of key
principles related to traditional meta-analyses and network meta-analyses [10] To
be extracted, information was required on the format for presenting the
information, not just that the information be provided or reported (i.e., focusing
on ‘how’ to report not just ‘what’ to report).
Detailed guidance on how to conduct a NMA was not extracted (e.g. analytic
approaches) and is not the focus of this systematic review.
Data Analysis
The frequency of recommendations for presenting NMAs was tabulated and
common trends assessed.
Results
Of the 1251 citations identified, 14 reports, representing 7 guidelines, were
included (see Fig. 1). [2, 22–34] Thirty reports were excluded, including a
background document from the Cochrane Collaboration on the history of
discussions within Cochrane on developing guidance for comparing multiple
interventions in Cochrane Reviews. [35]
Key characteristics of the guidelines are outlined in Table 1 with the purpose of
each guideline described in S3 Table.
All guidelines provided guidance on how to conduct NMA and three (43%)
also provided guidance on reporting NMA. [22–31] None of the guidelines were
directed to any specific disease area or intervention and were generally applicable
across all health technologies. Most guidelines (n55, 71%) were developed by
HTA organizations around the world with the others developed by collaboratives
with an interest in HTA, including the International Society For
Pharmacoeconomics and Outcomes Research (ISPOR) and the European network
for Health Technology Assessment (EUnetHTA). The target audience for all
guidelines was researchers and decision-makers; two guidelines (29%) also
identified health care professionals as part of the target audience. [29–31] Many
guidelines (n55, 71%) specifically acknowledged how policymakers or other non-
technical audiences use NMAs. However, only one guideline provided specific
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guidance regarding how to present NMAs to non-technical end-users [29–30]. For
example, guidance suggested converting outcomes to measures policymakers
might prefer such as relative risk, absolute risk reduction, number needed to treat.
[29–30] None of the guidelines provided a full glossary of technical terminology
used in NMAs, however three of the guidelines (43%) provided some definitions.
[29–30, 32, 34]
The earliest guideline was published in 2008. [34] Most guidelines recognized
the rapidly evolving field of NMA and noted that updates would be required and
guidelines would be monitored for these changes. Guideline quality was generally
low when critically appraised. Common limitations were related to narrow
stakeholder involvement, lack of systematic development and few details related to
Fig. 1. PRISMA Flow Diagram for Systematic Review of NMA Guidelines.
doi:10.1371/journal.pone.0113277.g001
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implementation and applicability of guidelines. Policymakers frequently provided
funding for the guidelines, however, authors’ conflicts of interest were not
reported in the majority of guidelines. Although recommendations were clearly
identified in most guidelines, differences in terminology when comparing across
guidelines may create confusion and lead to lack of clarity. More details on the
critical appraisal are provided in S4 Table.
Presentation Formats Identified in Guideline Recommendations,
Sample Figures and Sample Tables
Of the seven guidelines that met the inclusion criteria, only four (57%) provided
recommendations or guidance on presentation formats, as described in more
detail in sections below. None provided an example template for how to report
NMA. Although actual recommendations on how to present NMAs were not
provided in all guidelines, some example figures (n55, 71%) and tables (n54,
57%) were provided when illustrating how to conduct NMAs. Sample figures and
tables were generally related to presenting data sources (e.g. evidence network
diagrams, trial characteristics tables) or results (e.g. forest plots, tables comparing
direct and indirect estimates). These presentation formats are described in more
detail below as they relate to each section.
The different areas of NMAs for which presentation formats were identified or
recommended in guidelines and are outlined in Table 2.
Table 1. Characteristics of Network Meta-Analysis Guidelines.
Guideline
Geographic
Region Scope
Presentation
Formats
Recommended*
Sample
Figures*
Sample
Tables*
Reporting
Template
Glossary or
Definitions
Provided
Acknowledging
Non-Technical End-
Users**
ISPOR 2011 International
Collaboration
Reporting and
Conducting
Yes Yes Yes No Yes Yes
CADTH 2009 Canada Conducting No Yes No No No Yes
NICE DSU
Series 2011
UK Reporting and
Conducting
Yes Yes Yes No No Yes
PBAC 2008 Australia Conducting Yes No No No Yes Yes
HAS 2009 France Conducting No Yes Yes No No No
AHRQ 2010 USA Reporting and
Conducting
Yes No No No No Yes
EUnetHTA
2013
European
Collaboration
Conducting No Yes No No Yes No
Abbreviations: AHRQ5Agency for Healthcare Research and Quality; CADTH5Canadian Agency for Drugs and Technologies in Health;
EUnetHTA5European network for Health Technology Assessment; HAS5Haute Autorite de Sante´; ISPOR5International Society for Pharmacoeconomics
and Outcomes Research (ISPOR); NICE5National Institute for Health and Clinical Excellence; PBAC5Pharmaceutical Benefits Advisory Committee.
*Although actual recommendations on how to present NMAs were not provided in all guidelines, some example figures and tables were provided when
illustrating how to conduct NMA, which could inform how to present NMAs.
**Although most guidelines acknowledged there were non-technical end-users of NMAs, only one (ISPOR) provided specific guidance on how to present
information to them.
doi:10.1371/journal.pone.0113277.t001
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Presenting Data Sources/Included Data
Three guidelines (43%) made recommendations on presenting evidence networks.
[22–30, 34] All three recommended a graphical schematic of the evidence
structure, which are often referred to as ‘network diagrams’. These diagrams
outline relationships between the included studies and where direct and indirect
evidence exists between therapies in the network. Diagram characteristics in the
sample figures (n53, 43%) generally included features such as the use of solid
lines for direct evidence and dashed lines for indirect evidence relationships;
providing on the connecting line between two therapies the name, number of
trials or direct results contributing to a comparison; arrowheads indicating which
therapy is favoured in the comparison; and labeling or identifying the network
geometry, e.g. star shapes, closed loops. However, specific recommendations on
which features to include in the network diagram were not provided in any of the
guidelines.
Two of the guidelines recommended flow diagrams outlining included and
excluded studies and/or tables or lists identifying included and excluded studies.
[22–30] When presenting lists or tables of included and excluded studies,
clarifying which studies were identified in the systematic review versus which
studies had sufficient information to be included in the network meta-analysis
was requested in some guidelines. [22–30]
Four guidelines (57%) made recommendations on how to present details of
individual trials. Two guidelines recommended presenting information in a table
format [22–30] while the other two indicated it could be discussed in the text.
[31, 34] Individual trial details included what treatments were compared, trial
level data used in the analysis, trial level covariate values, or if individual
participant data are available. [22–28] Other factors that could be effect modifiers
Table 2. Network Meta-Analysis (NMA) Areas with Frequency of Presentation Formats Identified in Guidelines.
Areas of NMA Recommendations on Presentation Formats Formats Presented in Sample Figures or Tables
n (%), N57 n (%), N57
Included Data
Trial Network 3 (43) 3 (43)
Individual Trial Characteristics 4 (57) 4 (57)
Critical Appraisal 1 (14) 0
Methods
Assumptions 2 (29) 1 (14)
Heterogeneity and/or Inconsistency 4 (57) 1 (14)
Methodological Concerns 2 (29) 0
Results
Comparison of Direct and Indirect Effects 4 (57) 4 (57)
Uncertainty 3 (43) 4 (57)
Rankings 2 (29) 1 (14)
Implications of Findings 2 (29) 0
doi:10.1371/journal.pone.0113277.t002
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were recommended for inclusion in tables such patient age, length of time with a
disease, history of treatment or geographic region [29–30]. Two guidelines only
made broad recommendations that sufficient study-level characteristics be
provided and discussed. [31, 34] One guideline also specifically recommended
presenting an assessment of individual trial quality as discussion in the text. [22–
28]
When considering sample tables and figures related to data sources (n54,
57%), additional formats and characteristics were noted. For example, trial
sponsor, population, therapies and doses, trial duration, size of treatment group,
primary and secondary endpoints, blinding and study conclusions were included
in one sample table [33] Three guidelines also recommended a table where each
row is a study and each column is a treatment, with cells populated with absolute
frequencies from the trials, which can clarify where direct evidence exists in the
network while also demonstrating the raw data included in the analysis. [2, 22–30]
In one guideline, additional columns reporting relevant trial characteristics were
also added to the table. [22–30]
Presenting Analysis Methods
Two guidelines (29%) recommended presenting information on general
assumptions and on general methodological concerns as a description in the text.
[22–30] When looking at more specific assumptions, four guidelines (57%) made
recommendations on how to present issues related to heterogeneity and
inconsistency. Multiple formats for presenting this information were identified
including text descriptions, graphics and numerical estimates. For example, NICE
technical support documents suggested graphics generated by ‘node splitting’,
numerical estimates of the degree of heterogeneity, discussion of extent and
sources of heterogeneity and plotting posterior mean deviances to identify
inconsistencies. [22–28] Another guideline suggested presenting sensitivity
analyses of including/excluding trials and providing a discussion of potential
sources of heterogeneity. [34] Two other guidelines focused on presenting
descriptions that included explicit statements and step-by-step description of
analyses [29–30] or distinguishing between clinical, methodological and statistical
heterogeneity. [31]
When considering sample formats in guidelines related to methodology (n51,
14%), various plots were included that would allow one to explore methodo-
logical assumptions when conducting an NMA such as leverage plots, density
plots, interaction plots and residual deviance plots. [22–28] Sample table formats
were also identified that included measures of model fit and heterogeneity,
summary results for consistency and inconsistency models and that outlined
results from different sensitivity analyses with and without covariate interactions.
Guidelines on Presenting NMAs
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Presenting Results
Four guidelines (57%) made recommendations on how to present and compare
direct estimates with indirect or mixed estimates. Both table formats and forest
plots were recommended in two guidelines but there was no preference noted for
one format over the other. [22–30] Generally, these formats were recommended
so as to allow easy visual comparison of different results, e.g. outcomes by
treatment arm, absolute and relative effect measures from trials, pairwise meta-
analysis results and/or pooled NMA results. [22–30] Presenting results using a
common reference standard was noted in two guidelines [22–30] and one
guideline also recommended that all relevant pairwise comparisons should also be
provided. [29–30] Two guidelines also recommended the use of multiple
estimators to present results (e.g., relative risk, odds ratio, risk difference, number
needed to treat). [29–30, 34] Tables providing relative treatment effects alongside
estimates of heterogeneity were recommended in one guideline. [22–28] One
guideline recommended a discussion of why the estimates differed but did not
specify more details. [31]
Four guidelines (57%) provided sample tables that outlined direct, indirect
and/or mixed estimates in table columns while each row represented a
comparison of interest. [2, 22–30, 33] Other types of results were also compared in
this format (e.g. analytic approaches such as Bayesian vs. frequentist or different
sensitivity analyses). Two of these guidelines also provided samples of forest plots
that included direct, indirect and mixed estimates and allowed for easy visual
comparisons. [29–30, 33]
Three guidelines (43%) recommended presenting the uncertainty of estimates
as credible intervals or confidence intervals around the point estimate, depending
on the statistical analysis approach. [22–30, 34] In guidelines that provided sample
figures or tables (n54, 57%), these intervals were usually provided in table
columns or as a component of forest plots, along with the point estimate.
Two guidelines (29%) recommended presenting treatment rankings as either
graphics or tables. [22–30] There was also considerable discussion in the
guidelines on the challenges of presenting information on rankings so that it is not
misinterpreted. For example, ensuring the information on the spread of rankings
is provided [29–30] and that the probabilities of being best, second best, etc. are
calculated was recommended in both guidelines. [22–30] One guideline
specifically suggested presenting this information in the format of a rank-o-gram,
which can incorporate multiple outcomes in one display. [22–28] Other possible
formats published in peer-review literature were also recognized to be useful at
times. [22–28]
Only one guideline provided a sample format of how to present rankings. [29–
30] The guideline provided a table with each row being a different treatment
versus the reference comparators and columns of results (ORs, % CrI) and
columns of rankings and different probabilities of being best.
Two guidelines (29%) made recommendations on presenting the implications
of findings as descriptions in the text. One guideline specifically referred to the
implication of assumptions on results [22–28] The other identified implications
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with respect to validity of results; expectations compared with existing evidence,
clinical rationale or biological rationale; relevance to real-world clinical and policy
decisions; and the extent of possible bias and if it could lead to a different
conclusion than a non-biased analysis. [29–30]
Discussion
Key Findings
Current NMA guidelines focus on how to conduct analyses but provide limited
guidance to researchers on how to best present analyses. None of the guidelines
provided reporting templates. Few provided specific advice on tailoring
presentations to different end-users or extensive glossaries for non-technical
readers, despite many guidelines being developed in HTA organizations for use, in
part, by policymakers. Only four of the seven included guidelines provided advice
on presentation formats or provided sample figures and tables to guide
presentation of the NMA. This guidance focused primarily on presenting evidence
networks, characteristics of individual trials, comparisons between direct and
indirect estimates and assumptions of heterogeneity and/or inconsistency.
Comparison with Other Literature and Policy Implications
Although reporting guidelines exist in other fields (e.g., economic evaluations,
systematic reviews), due to the relatively innovative nature of NMAs, guidelines
for the reporting and conducting of NMAs are less well-developed. Currently,
NMA guidelines focus on defining standard methodological approaches and
increasing the consistency and transparency of how NMAs are conducted.
Corroborating this, two other reviews of NMA guidelines were identified but they
compared methodological recommendations across guidelines and did not
explore best practices of how to present NMAs to different audiences. [5, 36] The
limited guidance may also be influenced by the evolving methodological
approaches (e.g. Bayesian versus frequentist analyses) and various available
software (e.g. WinBugs, STATA, SAS) that restrict how NMAs can be presented.
Development of more universal and user-friendly software programmes could
also contribute to assisting researchers in enhancing and standardizing how
NMAs are presented for various end-users. However, with the growing use of
NMAs and greater need for policymakers and other non-technical end-users to
understand NMAs, determining how best to present NMAs has taken on greater
prominence. [3]
The areas that were frequently identified in existing guidelines provide a
starting point for focusing guidance for non-technical end-users, with
interpretations offered in light of these end-users needs in using and under-
standing NMAs:
N Inclusion of trial details and network diagrams. This will also align with
policymakers’ need to understand the applicability of the analysis to their
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specific decision-making context. Providing graphical schematics (i.e., evidence
network diagrams) may also help audiences better understand the relationships
among the included studies. Looking at the shape of the network itself (e.g. star
diagram, number of closed loops) can provide information on characteristics of
the included evidence. [37, 38] In addition, there are many other styles of
network diagrams that have been reported in literature and other trial
characteristics that can be included (e.g. sample size, risk of bias). [11] Even
though many guidelines provided examples of network diagrams, few
guidelines made specific recommendations on their design or how to tailor
them to policymakers and clinicians.
N Comparison between direct and indirect results. Questions often arise on why
direct and indirect estimates may differ from each other and explanations could
assist end-users. Although, NMA results may be complex, building on familiar
approaches used to present traditional meta-analyses (e.g. forest plots) may
provide end-users and researchers with greater comfort with and under-
standing of how to interpret NMA results. [10]
N Heterogeneity and inconsistency assumptions. Identifying presentation
formats that provide audiences with clarity on the assumptions made in the
analysis and help end-users understand their validity would be of value.
Although assumptions other than heterogeneity and inconsistency are
important in conducting NMAs (e.g. goodness of fit, random effects), different
methods of presenting the validity of these other assumptions were not often
noted.
Further developing guidelines for researchers on how to best present these
aspects of NMAs to end-users of NMAs such as policymakers or others who want
to enhance their understanding of NMAs should be considered in light of:
a) Policymakers’ preferences for evidence syntheses. Although policymakers may
have limited experience with NMAs, they have often expressed views on how
to present systematic reviews and traditional meta-analyses. Studies have
reported that policymakers prefer presentation formats that can be quickly
scanned, emphasize the bottom-line conclusions and clearly identify real-
world implications [39–41]. Policymakers have also expressed a desire for
understanding if the review is robust enough from a methodological
perspective, to support decision-making. [12] Incorporating policymakers’
preferences at this stage in the development of NMA guidelines would narrow
the gap between policymakers and researchers when using and providing
NMAs. This would also allow for the creation of NMAs that adequately
balance both rigour and accessibility for those who must apply their results
and understand their implications in the ‘real-world’. A recent ISPOR task
force partially addresses this gap by developing a questionnaire for decision-
makers to assess the relevance and credibility of NMAs. [12]
b) Common principles related to the presentation of traditional meta-analyses.
NMAs are based on many of the same principles as traditional meta-analyses.
[10, 42]. Leveraging some of these same principles may be one approach that
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could help end-users better understand and appreciate NMAs. For example,
conducting systematic searches for evidence, verifying homogeneity of
populations when combining individual study results and presenting results
with appropriate measures of precision or uncertainty are principles
applicable to both traditional meta-analyses and NMAs.
c) How researchers currently present NMAs. Current presentation of NMAs by
researchers is extremely variable. This variability may be due, in part, to the
range of current methodological approaches to conducting NMAs, software
restrictions and the evolving methodology in the field of NMA. For example,
Tan et al. (2013) reviewed 19 indirect treatment comparisons (IDCs) from
NICE health technology assessments and found that researchers most
frequently presented evidence network diagrams, model descriptions and
tables and forest plots of results. [15] Based on this work approaches that may
be most useful for non-technical audiences were identified and standardized
graphical tools were developed that compare direct with indirect results and
that summarize rankings. [16] An analysis from Chiamani et al. (2013) has
also proposed new graphical options for presenting NMA methods and results
that were developed using STATA. [7] For example, network diagrams that
incorporate key trial characteristics and risk of bias assessments and
contribution plots that emphasize how much direct versus indirect evidence
is available in the analysis. Evaluating these different tools and formats to
determine if they influence use or understanding of NMAs would be
beneficial.
d) Common limitations associated with conducting NMAs. Common limita-
tions in NMAs may need to be presented very clearly for non-technical
audiences. In a survey of 88 indirect comparisons, limitations included: an
unclear understanding of underlying assumptions; inappropriate search for or
selection of included trials; inappropriate or flawed methods; trial similarity
not being objectively assessed; and an inappropriate combination of direct
and indirect evidence. [43] A report on indirect comparisons submitted to
NICE reported similar results, finding that common flaws were related to
systematic review search methods, inappropriate pooling of heterogeneous
data and suboptimal statistical methods. [44] More consistent reporting
standards and optimized presentation formats in these areas may result in
more clarity around expectations when conducting NMAs and ultimately
enhance their quality.
Even with these considerations on how to optimize and tailor the presentation
of NMAs to different end-users, the understanding and interpretation of NMAs
may be challenging for non-technical end-users. The optimal presentation of
NMAs should be considered as only one approach to build capacity in the field of
NMAs and should be applied in concert with educational initiatives such as
tutorials and workshops. For example, although few guidelines included glossaries
of NMA terminology, glossaries or other tools may be available through other
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sources that are available to end-users (e.g., Cochrane Comparing Multiple
Interventions Methods Group website, http://cmimg.cochrane.org).
Strengths and Limitations
This is the first work to systematically review the guidance that researchers are
provided on how to present NMAs and interpret these findings in the context of
policymakers and other non-technical audiences. Identification of variables to
extract was grounded in theoretical concepts of how NMAs relate to traditional
meta-analyses. [10] Using this approach and building on traditional meta-analysis
concepts could provide one avenue to facilitate understanding of NMAs among
audiences familiar with traditional meta-analyses.
Methodological guidelines do not exist to critically appraise the quality of NMA
guidelines and a tool for critically appraising clinical practice guidelines was
adapted. Therefore, concepts unique to methodological guidelines may have been
missed, however, the appraisal allowed identification of some key issues in the
guidelines’ development. For example, few guidelines reported authors’ affilia-
tions and/or conflicts of interest that may have influenced guideline recommen-
dations. Conflict of interest may comprise not only financial interests but also
intellectual conflicts such as guideline authors promoting methods with which
they have the most experience. Given the small pool of experts in the emerging
field of NMAs, it is challenging to determine the impact of intellectual conflict of
interest; more time may be required before sufficient experience with different
methods emerges and best practices in presenting NMAs can be identified that
have widespread acceptability. Furthermore acceptability of guidelines by
researchers and other end-users often depends on the level of stakeholder
involvement in their development and consideration around how they will be
implemented in practice. The quality of most guidelines was low around these
aspects and should be considered in future if more efforts are devoted to
enhancing guidelines on how to present NMAs for different stakeholders.
Extracting qualitative data from various guideline documents requires judgment.
The heterogeneity of guideline formats and objectives created challenges in data
synthesis, however, common factors such as their development by HTA
organizations and consideration of both researchers and policymakers suggests
they have a similar intent. Also, the limited information available on presentation
formats and broad data definitions applied in this review suggests that
misclassification of data was unlikely to occur, e.g. it was unlikely that a figure
presenting data sources would be missed or misclassified as a figure presenting
results. A comprehensive search of the grey literature, electronic databases and
other sources allowed for identification of a broad set of possible NMA guidelines.
Although partial guidelines were excluded from this review, the novel but evolving
nature of NMA guidance suggests they were not likely to yield additional data.
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Future Research and Conclusions
The focus on developing presentation formats should be in areas that were most
frequently raised in current NMA guidelines and are important to researchers,
including: trial details and evidence network diagrams; comparisons between
direct and indirect results; and heterogeneity and inconsistency assumptions.
However, limited guidance exists for researchers on how best to present NMAs in
an accessible format for policymakers and requires further thought, and
integration with policymakers needs. Knowledge translation approaches have
frequently been applied to enhancing understandability and accessibility of clinical
trial evidence for policy makers, healthcare providers and patients [45–47].
Tailored knowledge translation approaches have presented evidence syntheses in
formats such as 1000 faces in decision aids and key messages in briefing notes
tailored to policy makers [45–46]. Expansion of these approaches to NMAs has
not yet occurred, but could be applied to develop technically accurate but
simplified explanations of NMAs for policy makers or other non-technical
audiences. For example, in addition to providing technical reports and scientific
publications of NMAs, decision support tools could be developed. Tools could
also be used to inform other educational initiatives or supplementary resources
for policy makers and other general audiences to understand NMAs. Development
of tailored presentation formats will allow policy makers to better apply the results
of NMAs and enhance the transparency and legitimacy of HTA-informed
decision-making processes.
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